Brief: Orchard Therapeutics Says $150 Mln Strategic Financing Supports Execution Into First Half Of 2023
02/03/2021 12:10
March 2 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND
REVIEWS
RECENT ACCOMPLISHMENTS
* ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC
FINANCING
SUPPORTS EXECUTION INTO FIRST HALF OF 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 U.S. FILING STRATEGY
FOR
METACHROMATIC LEUKODYSTROPHY (MLD) EXPECTED BY MID-2021
Source text for Eikon: ID:nGNX7qZyxz
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln